PepEvolutionSemaglutide
Ozempic / Wegovy
The most-studied GLP-1 agonist — FDA-approved, landmark cardiac outcomes trial — but gray-market counterfeits are rampant.
Verdict — B · Viable
The best human-evidence story in the GLP-1 class, but the gray-market counterfeit problem and a real safety burden (boxed thyroid warning, GI toll, lean-mass loss) keep it firmly in B territory. Buy it verified or through a licensed provider.
Overview
Semaglutide is a GLP-1 receptor agonist approved by the FDA for type-2 diabetes (Ozempic) and obesity (Wegovy), with landmark evidence from STEP and SELECT trials totaling tens of thousands of participants and a proven cardiovascular mortality benefit. The science is unimpeachable. The sourcing reality is not: the gray-market supply is flooded with counterfeit and mislabeled vials, and the safety profile carries a boxed thyroid C-cell warning, significant GI burden, and lean-mass concerns.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.